MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK‐mediated HER 2 phosphorylation at Thr701
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Targeting the MEK/ERK pathway has been viewed as a promising strategy for cancer therapy. However, MEK inhibition leads to the compensatory PI 3K/AKT activation and thus contributes to the desensitization of cancer cells to MEK inhibitors. The underlying molecular mechanism of this event is not yet understood. In this study, our data showed that the induction of Akt activity by MEK inhibitors was specifically observed in HER 2‐positive breast cancer cells. Silence of HER 2, or overexpression of HER 2 kinase‐dead mutant, prevents the induction of Akt activation in response to MEK inhibition, indicating HER 2 as a critical regulator for this event. Furthermore, HER 2 Thr701 was demonstrated as a direct phosphorylation target of ERK 1/2. Inhibition of this specific phosphorylation prolonged the dimerization of HER 2 with EGFR in a clathrin‐dependent manner, leading to the enhanced activation of HER 2 and EGFR tyrosine kinase and their downstream Akt pathway. These results suggest that suppression of ERK‐mediated HER 2 Thr701 phosphorylation contributes to MEK inhibitor‐induced Akt activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4000 · Cited by 606 · cited 1×
“Consequently, many cancers bearing these MAPK-related mutant genes exhibit a survival addiction to ERK1/2 signaling (Caunt et al., 2015; Kidger and Keyse, 2016).”
BackgroundMEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors
Turke, A. B., Song, Y., Costa, C., Cook, R., Arteaga, C. L., Asara, J. M., & Engelman, J. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3747 · Cited by 368
Cited by
Cell Type–Specific Adaptive Signaling Responses to KRASG12C Inhibition
Solanki, H. S., Welsh, E. A., Fang, B., Izumi, V., Darville, L., Stone, B., Franzese, R., Chavan, S., Kinose, F., Imbody, D., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3872 · Cited by 106
“ERBB receptor dimer formation (30) and MEK inhibition induced ERBB/Akt signaling activation by suppressing HER2 pT701 phosphorylation (31).”
BackgroundCell signaling and cancer: a mechanistic insight into drug resistance
Panda, M., & Biswal, B. K. (2019) · Molecular Biology Reports · doi:10.1007/s11033-019-04958-6 · Cited by 89
Proteomic analyses identify targets, pathways, and cellular consequences of oncogenic KRAS signaling
Kabella, N., Bayer, F. P., Stamatiou, K., Abele, M., Sakhteman, A., Chang, Y.-C., Wagner, V., Gabriel, A., Krumm, J., Reinecke, M., et al. (2025) · Science Signaling · doi:10.1126/scisignal.adt6552 · Cited by 8
Metadata
- Authors
- Chen, C., Hsia, T., Yeh, M., Chen, T., Chen, Y., Chen, J., Wei, Y., Tu, C., & Huang, W.
- Venue
- Molecular Oncology
- Publisher
- Wiley
- Published
- 2017-07-19
- Volume
- 11
- Issue
- 9
- Pages
- 1273-1287
- ISSN
- 1574-7891 (ISSN-L)
- 1878-0261
- OpenAlex
- W2657204133
- Cited by
- 64
- References
- 2
- FWCI
- 2.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK‐mediated HER 2 phosphorylation at Thr701. https://app.cochat.ai/papers/10.1002/1878-0261.12102
- The paper
- Chen, C., Hsia, T., Yeh, M., Chen, T., Chen, Y., Chen, J., Wei, Y., Tu, C., & Huang, W. (2017). MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK‐mediated HER 2 phosphorylation at Thr701. Molecular Oncology. https://doi.org/10.1002/1878-0261.12102
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.